1-(Bromomethyl)-4-(trifluoromethoxy)benzene → 6-(2,6-Dimethoxyphenyl)-4,4-dimethyl-1-(4(trifluoromethoxy)benzyl)piperidin-2-one
반응식
[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[C:5]([O:9][CH3:10])[C:4]=1[CH:11]1[NH:16][C:15](=[O:17])[CH2:14][C:13]([CH3:19])([CH3:18])[CH2:12]1.Br[CH2:21][C:22]1[CH:27]=[CH:26][C:25]([O:28][C:29]([F:32])([F:31])[F:30])=[CH:24][CH:23]=1>>[CH3:1][O:2][C:3]1[CH:8]=[CH:7][CH:6]=[C:5]([O:9][CH3:10])[C:4]=1[CH:11]1[N:16]([CH2:21][C:22]2[CH:27]=[CH:26][C:25]([O:28][C:29]([F:30])([F:31])[F:32])=[CH:24][CH:23]=2)[C:15](=[O:17])[CH2:14][C:13]([CH3:19])([CH3:18])[CH2:12]1참가 물질
3
실험 절차
Prepared according to the described general procedure 4 (GP4) by reaction of 6-(2,6-dimethoxyphenyl)-4,4-dimethylpiperidin-2-one with commercially available 1-(bromomethyl)-4-(trifluoromethoxy)benzene. Subsequent purification by preparative HPLC afforded the target compound. LC-MS (conditions D): tR=1.14 min.; [M+H]+: 437.96 g/mol.
후처리
- customPrepared
- customSubsequent purification by preparative HPLC
- customafforded the target compound